Expression of membrane complement regulators, CD46, CD55 and CD59, in mesothelial cells of patients on peritoneal dialysis therapy. Issue 2 (June 2015)

• Record Type: Journal Article
• Authors: Sei, Yumi; Mizuno, Masashi; Suzuki, Yasuhiro; Imai, Masaki; Higashide, Keiko; Harris, Claire L.; Sakata, Fumiko; Iguchi, Daiki; Fujiwara, Michitaka; Kodera, Yasuhiro; Maruyama, Shoichi; Matsuo, Seiichi; Ito, Yasuhiko
• Is Part Of: Molecular immunology. Volume 65:Issue 2(2015:Jun.)
• Page Start: 302
• Page End: 309
• Publication Date: 2015-06
• Subjects: Complement -- Membrane complement regulators -- Peritoneal dialysis -- D/P creatinine -- CD55; Adjusted sC5b-9, C3, C4, IL-6 or CA 125 levels of sC5b-9, C3, C4, IL-6 or CA125 adjusted by protein levels -- αSMA α-smooth muscle actin -- Average MFI value of MFI as the mean MFI of three independent experiments -- β2MG β2-microglobulin -- BMI body mass index -- CA-125 carcinogenic antigen 125 -- CCre renal clearance of creatinine -- C complement -- CReg membrane complement regulator -- CKD chronic kidney disease -- DM diabetes -- DAPI 49-6-diamino-2-phenylindole-2 HCl -- D/P Cre dialysate-to-plasma creatinine concentration ratio -- ELISA enzyme-linked immunosorbent assay -- ESRD end-stage renal disease -- FACS fluorescence-activated cells sorting -- FITC fluorescein isothiocyanate -- HOMC primary culture of mesothelial cells harvested from human omentum -- HPMC primary cultures of mesothelial cells harvested from PD fluid -- HS normal human serum -- Kt/V urea renal clearance of urea -- mAb monoclonal antibody -- MFI mean fluorescence intensity -- pc polyclonal -- PD peritoneal dialysis -- PDF PD fluid -- RRT renal replacement therapy -- ZO-1 zonula occludens-1; Immunochemistry -- Periodicals; Molecular biology -- Periodicals; Immunochemistry -- Periodicals; Allergy and Immunology -- Periodicals; Molecular Biology -- Periodicals; Immunochimie -- Périodiques; Biologie moléculaire -- Périodiques; Immunochemistry; Molecular biology; Periodicals; Electronic journals; 571.96
• DOI: 10.1016/j.molimm.2015.02.005
• Languages: English
• ISSNs: 0161-5890

Abstract

Highlights: Membrane complement regulators abundantly express in peritoneal mesothelial cells. Mesothelial expression of CD55 was related to sC5b-9 level in peritoneal dialysate. Decrease of CD55 expression might enhance complement activation in mesothelial cells. Peritoneal dialysis therapy may modify expression of CD55 in peritoneum. Expression of CD55 in mesothelium may be a surrogate marker of peritoneal function. Abstract: We investigated the expression of membrane complement regulators (CRegs), CD46, CD55 and CD59 in human mesothelial cells, and correlated with clinical background and level of complement (C) activation products in peritoneal dialysis (PD) fluids (PDF) to clarify influence of the C activation system in PD patients. Expression of CRegs was assessed on primary cultures of mesothelial cells (HPMC) harvested from PD fluid of 31 PD patients. Because expression of CD55 but not CD46 and CD59 in mesothelial cells was significantly correlated to value of dialysate-to-plasma creatinine concentration ratio (D/P Cre) ( p < 0.005) as an indicator of peritoneal function, we focused on analysis of CD55 expression of HPMCs in comparison with levels of C activation products in the PDF of the PD patients, and their background factors. When comparing expression of the CRegs between systemic neutrophils and HPMC, no correlation was observed, supporting that change of CRegs' expression in HPMC was independently occurring in the peritoneum. Expression of CD55 protein in HPMC was closely correlated with expression at the mRNA level ( p < 0.0001) and was inversely correlated with levels of sC5b-9 ( p < 0.05), but not C3, C4, IL6 and CA125 in the PDF. Complications of diabetes, usage of icodextrin and residual renal function were not correlated with change of CD55 expression in HPMCs. Our data show that the process of PD therapy modifies expression of CD55 on peritoneal mesothelium and triggers local C activation. These findings support efforts to modify PD therapy to limit effects on activation and regulation of the C system.